Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands.
Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Euro Surveill. 2019 May;24(18). doi: 10.2807/1560-7917.ES.2019.24.18.1800363.
IntroductionEstimating burden of disease (BoD) is an essential first step in the decision-making process on introducing new vaccines into national immunisation programmes (NIPs). For varicella, a common vaccine-preventable disease, BoD in the Netherlands was unknown.AimTo assess national varicella BoD and compare it to BoD of other vaccine-preventable diseases before their introduction in the NIP.MethodsIn this health estimates reporting study, BoD was expressed in disability-adjusted life years (DALYs) using methodology from the Burden of Communicable Diseases in Europe (BCoDE)-project. As no parameters/disease model for varicella (including herpes zoster) were available in the BCoDE toolkit, incidence, disease progression model and parameters were derived from seroprevalence, healthcare registries and published data. For most other diseases, BoD was estimated with existing BCoDE-parameters, adapted to the Netherlands if needed.ResultsIn 2017, the estimated BoD of varicella in the Netherlands was 1,800 (95% uncertainty interval (UI): 1,800-1,900) DALYs. Herpes zoster mainly contributed to this BoD (1,600 DALYs; 91%), which was generally lower than the BoD of most current NIP diseases in the year before their introduction into the NIP. However, BoD for varicella was higher than for rotavirus gastroenteritis (1,100; 95%UI: 440-2,200 DALYs) and meningococcal B disease (620; 95%UI: 490-770 DALYs), two other potential NIP candidates.ConclusionsWhen considering the introduction of a new vaccine in the NIP, BoD is usually estimated in isolation. The current approach assesses BoD in relation to other vaccine-preventable diseases' BoD, which may help national advisory committees on immunisation and policymakers to set vaccination priorities.
引言
评估疾病负担(BoD)是将新疫苗引入国家免疫规划(NIP)决策过程中的重要第一步。对于水痘这种常见的疫苗可预防疾病,荷兰的 BoD 情况尚不清楚。
目的
评估荷兰的全国水痘 BoD,并将其与其他在引入 NIP 之前的疫苗可预防疾病的 BoD 进行比较。
方法
在本健康估计报告研究中,使用欧洲传染病负担(BCoDE)项目中的方法,以残疾调整生命年(DALYs)来表示 BoD。由于 BCoDE 工具包中没有水痘(包括带状疱疹)的参数/疾病模型,因此发病率、疾病进展模型和参数是从血清流行率、医疗保健登记和已发表的数据中得出的。对于大多数其他疾病,使用现有的 BCoDE 参数来估计 BoD,并根据需要进行荷兰的调整。
结果
2017 年,荷兰水痘的估计 BoD 为 1800(95%置信区间(UI):1800-1900)DALYs。带状疱疹主要导致了这一 BoD(1600 DALYs;91%),通常低于在引入 NIP 之前的当年大多数当前 NIP 疾病的 BoD。然而,水痘的 BoD 高于轮状病毒胃肠炎(1100;95%UI:440-2200 DALYs)和脑膜炎 B 型疾病(620;95%UI:490-770 DALYs),这两种疾病都是其他潜在的 NIP 候选疾病。
结论
当考虑在 NIP 中引入新疫苗时,BoD 通常是孤立地进行估计的。目前的方法是根据其他疫苗可预防疾病的 BoD 来评估 BoD,这可能有助于国家免疫咨询委员会和政策制定者确定疫苗接种的优先顺序。